Cellebration Life Sciences, Inc. — Form D/A
Cellebration Life Sciences, Inc. of PHOENIX, AZ, a company, filed a Form D amendment with the SEC on 2022-06-13. The offering totals $20.0M, of which $1.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-06-13
- Form: D/A
- Accession: 0001863013-22-000002
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $20.0M
- Amount sold: $1.3M
- Remaining: $18.7M
- Minimum investment: $25K
- Investors: 14
- Date of first sale: 2021-01-18
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-401437
Issuer
- Name: Cellebration Life Sciences, Inc.
- CIK: 0001863013
- Entity type: Corporation
- Jurisdiction: WYOMING
- Incorporated: 2020
- Address: 12601 N. CAVE CREEK ROAD, SUITE 111, PHOENIX, AZ, 85022
- Phone: 602-601-5293
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| Anand Srivastava | Director | San Diego, CA |
| Deven Patel | Director | San Diego, CA |
| Bill Deegan | Director | Phoenix, AZ |
| Tim Kopatich | Executive Officer | Phoenix, AZ |
Other filings by this issuer (3)
More